A Study of CC-97540 (BMS-986353 or Zola-cel), CD19-Targeted NEX-T CAR T Cells, in Participants With Active SLE Despite Immunosuppressants (Breakfree-SLE)

Inclusion Criteria:

• Participants must meet EULAR/ACR 2019 criteria for SLE.

• Participants must have an inadequate response to appropriate doses ofglucocorticoids and ≥ 2 immunosuppressant therapies, used for at least 3 months.

• Participants must have active disease when signing ICF.

Exclusion Criteria:

• Participants must not have other diseases, conditions, or treatments that mayconfound interpretation of the effects of CC-97540 in SLE.

• Uncontrolled or clinically significant cardiovascular conditions or CNS pathologyparticipants must not have prior history of malignancies or lymphoproliferativedisease, unless the participant has been free of the disease for ≥ 2 years, exceptfor some non-invasive malignancies.

• IOCBP who are pregnant, nursing, or breastfeeding, or who intend to become pregnant.

• Participants must not have prior treatment with CAR T cell therapy, geneticallymodified T cell therapy, stem cell transplant or organ transplant.

• Participants must not have received live vaccines within 6 weeks before LDC (lymphodepleting chemotherapy) administration.

• Participant must not have inadequate organ function.

• Other protocol-defined inclusion/exclusion criteria apply.